Reports Q1 revenue $93.5M, consensus $87.5M. "We had an extraordinary start to 2023 driven by strength across our platforms globally. We are experiencing robust demand from physicians to treat patients and remain excited for the extensive opportunities in our markets," said Michael Carrel, CEO. "As we look forward, we are focused on growing our patient impact, expanding clinical science and innovation, and increasing leverage across our operations."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATRC:
